Larimar Therapeutics, Inc.(LRMR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LRMR Larimar Therapeutics, Inc.

Post-Mkt 11-04 17:42:10 EST

2.76

+0.22

+8.66%

盘后2.76

+0.000.00%

16:10 EST

High2.78	Low2.57	Vol1.99M
Open2.60	D1 Closing2.54	Amplitude8.27%
Mkt Cap287.04M	Tradable Cap158.81M	Total Shares104.00M
T/O5.35M	T/O Rate3.46%	Tradable Shares57.54M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LRMR","market":"US","secType":"STK","nameCN":"Larimar Therapeutics, Inc.","latestPrice":2.76,"timestamp":1793826000000,"preClose":2.54,"halted":0,"volume":1991396,"hourTrading":{"tag":"盘后","latestPrice":2.76,"preClose":2.76,"latestTime":"16:10 EST","volume":8191,"amount":22607.16,"timestamp":1793826604188,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.08661417322834636,"floatShares":57541600,"shares":104000000,"eps":-1.925766,"marketStatus":"Post-Mkt","change":0.22,"latestTime":"11-04 17:42:10 EST","open":2.6,"high":2.78,"low":2.57,"amount":5352586,"amplitude":0.082677,"askPrice":3.08,"askSize":100,"bidPrice":2.18,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.925766,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1793840400000},"marketStatusCode":4,"adr":0,"listingDate":1403150400000,"exchange":"NASDAQ","adjPreClose":2.54,"preHourTrading":{"tag":"盘前","latestPrice":2.56,"preClose":2.54,"latestTime":"09:11 EST","volume":7311,"amount":18779.6180178,"timestamp":1793801497145,"change":0.02,"changeRate":0.007874,"amplitude":0.133858},"postHourTrading":{"tag":"盘后","latestPrice":2.76,"preClose":2.76,"latestTime":"16:10 EST","volume":8191,"amount":22607.16,"timestamp":1793826604188,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":2.017862,"impliedVol":0.1934,"impliedVolPercentile":0.0359},"requestUrl":"/m/hq/s/LRMR","defaultTab":"news","newsList":[{"id":"2681761060","title":"Larimar Therapeutics Participates in Guggenheim Healthcare Innovation Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2681761060","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681761060?lang=en_us&edition=fundamental","pubTime":"2026-11-05 05:17","pubTimestamp":1793827058,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics Participates in Guggenheim Healthcare Innovation ConferenceLarimar Therapeutics will attend the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston Nov. 9-11, 2026.Ma","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nNDL9TsRqv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","IE00BQXX3F31.USD","LU2095319765.USD","SG9999014005.SGD","BK4585","BK4588","SG9999014013.SGD","IE00BQXX3C00.GBP","NDAQ","IE00BN0W2W23.USD","LU2210150020.SGD","BK4139","SG9999014021.USD","IE00BN0W2V16.EUR","BCDF","IE00BQXX3D17.EUR","LU0314104364.USD","LRMR","LU2210149790.SGD","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672843762","title":"Larimar Therapeutics President, COO John B. Harlow Jr. Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2672843762","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672843762?lang=en_us&edition=fundamental","pubTime":"2026-10-02 04:27","pubTimestamp":1790886440,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics President, COO John B. Harlow Jr. files initial beneficial ownership statementLarimar Therapeutics filed an initial Form 3 for John B. Harlow Jr., president and COO, dated Sept. 2","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nNDL6jWwYH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LRMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671242056","title":"Larimar Therapeutics appoints John Harlow as COO","url":"https://stock-news.laohu8.com/highlight/detail?id=2671242056","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671242056?lang=en_us&edition=fundamental","pubTime":"2026-09-30 04:15","pubTimestamp":1790712916,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics (LRMR) announced the appointment of John Harlow as President and COO, effective September 29, reporting to Carole Ben-Maimon, ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/larimar-therapeutics-appoints-john-harlow-as-coo-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/larimar-therapeutics-appoints-john-harlow-as-coo-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","LRMR","LENZ","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671242178","title":"Larimar Therapeutics Names John Harlow President and COO","url":"https://stock-news.laohu8.com/highlight/detail?id=2671242178","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671242178?lang=en_us&edition=fundamental","pubTime":"2026-09-30 04:05","pubTimestamp":1790712350,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics names John Harlow president and COOLarimar Therapeutics named John Harlow president and chief operating officer, effective Sept. 29, 2026, reporting to CEO Carole Ben-Maimon.Harlo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nNDL3WtsDR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","BK4588","LU2210149790.SGD","IE00BQXX3C00.GBP","IE00BN0W2T93.GBP","SG9999014021.USD","BK4112","BK4585","IE00B64PRP62.GBP","IE00BKPKM429.USD","SG9999014039.USD","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","LU0314104364.USD","LU2210150020.SGD","IE00BN0W2W23.USD","SG9999014005.SGD","IE00BQXX3F31.USD","NDAQ","LU2095319765.USD","LRMR","BCDF","BXRXQ","BK4139","BK4007","IE00B3QW5Z07.USD","IE00BQXX3D17.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671242139","title":"Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2671242139","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671242139?lang=en_us&edition=fundamental","pubTime":"2026-09-30 04:05","pubTimestamp":1790712300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nTUA90JXSC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LRMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670398762","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Neogen (NEOG), Larimar Therapeutics (LRMR) and Sagimet Biosciences, Inc. Class A (SGMT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2670398762","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670398762?lang=en_us&edition=fundamental","pubTime":"2026-09-28 18:20","pubTimestamp":1790590815,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Neogen (NEOG), Larimar Therapeutics (LRMR) and Sagimet Bioscience...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-neogen-neog-larimar-therapeutics-lrmr-and-sagimet-biosciences-inc-class-a-sgmt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-neogen-neog-larimar-therapeutics-lrmr-and-sagimet-biosciences-inc-class-a-sgmt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","LU0029874061.USD","BK4588","LABU","HCSG","NEOG","BK4139","XLV","BK4198","BK4585","SGMT","LU0128526141.USD","BK4581","LRMR","LU2211817866.USD","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667657172","title":"U.S. Research Roundup-ACV Auctions, Crown Castle, Lennox International","url":"https://stock-news.laohu8.com/highlight/detail?id=2667657172","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667657172?lang=en_us&edition=fundamental","pubTime":"2026-09-14 18:22","pubTimestamp":1789381349,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-ACV Auctions, Crown Castle, Lennox InternationalSept 14 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, includ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nL4N4560NX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MARA","LRMR","DINO","MARO","FLNC","GXPE","MPC","ADBE","CALY","EBAY","ALGT","CCI","GSIT","DBI","SMOG","BE","CPK","JKHY","LII","ADBG","GM","CEVA","KR","EIX","FIG","MAAY","ADUS","OWNB","KRSA","DK","DRI","DFTX","EXP","LYNX","CAPR","DTCR","DVN","XTN","FRSH","CRWV","AZO","EGP","BEX","ECHO","ERII","FCNCA","ACVA","CPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666454537","title":"Century Therapeutics Appoints Joseph Truitt to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2666454537","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666454537?lang=en_us&edition=fundamental","pubTime":"2026-09-10 04:05","pubTimestamp":1788984300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nTUA8SM16N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","LRMR","IPSC","BK4505","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656530538","title":"Larimar Therapeutics Q2 EPS USD -0.3","url":"https://stock-news.laohu8.com/highlight/detail?id=2656530538","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656530538?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:00","pubTimestamp":1785841205,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nPLXRXRK87:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LRMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656530430","title":"Larimar Therapeutics - Projects Cash Runway into Q3 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2656530430","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656530430?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:00","pubTimestamp":1785841205,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nPLXRXRK87:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LRMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656308055","title":"Larimar Therapeutics Q2 Net Income USD -32.782 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2656308055","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656308055?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:00","pubTimestamp":1785841205,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nPLXRXRK87:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LRMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656530844","title":"Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2656530844","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656530844?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:00","pubTimestamp":1785841204,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nTUA92TBLY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LRMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651790170","title":"Exploring 3 High Growth Tech Stocks In The US Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2651790170","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651790170?lang=en_us&edition=fundamental","pubTime":"2026-07-14 19:08","pubTimestamp":1784027291,"startTime":"0","endTime":"0","summary":"In the last week, the United States market has stayed flat, yet it has risen 19% over the past year, with earnings expected to grow by 18% annually in the coming years. In such a dynamic environment, identifying high growth tech stocks can be key for investors seeking to capitalize on innovation and robust financial performance.","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rzlt/rezolute/news/exploring-3-high-growth-tech-stocks-in-the-us-market-80","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rzlt/rezolute/news/exploring-3-high-growth-tech-stocks-in-the-us-market-80","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2360032135.SGD","BK4161","RZLT","LU2125154935.USD","LPTH","BK4157","LU0128526141.USD","HI","LRMR","LU2125154778.USD","BK4139","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650748915","title":"Larimar Therapeutics director buys $167K in common stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2650748915","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650748915?lang=en_us&edition=fundamental","pubTime":"2026-07-09 04:10","pubTimestamp":1783541411,"startTime":"0","endTime":"0","summary":"In a regulatory filing, Larimar Therapeutics (LRMR) disclosed that its director, Thomas Hamilton, bought 50,000 shares of common stock on July 6th ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/larimar-therapeutics-director-buys-167k-in-common-stock-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/larimar-therapeutics-director-buys-167k-in-common-stock-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4539","BK4139","LRMR","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650903915","title":"Larimar Therapeutics Director Thomas Edward Hamilton Acquires USD 166,890 of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2650903915","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650903915?lang=en_us&edition=fundamental","pubTime":"2026-07-09 04:06","pubTimestamp":1783541177,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics director Thomas Edward Hamilton acquires USD 166,890 of common sharesLarimar Therapeutics director Thomas Edward Hamilton bought 50,000 common shares at a weighted-average price o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260708:nNDL16NRLc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Larimar Therapeutics Director Thomas Edward Hamilton Acquires USD 166,890 of Common Shares","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LRMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648696779","title":"Adobe, Larimar, Palantir, Chevron, eXp Trending With Analysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2648696779","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648696779?lang=en_us&edition=fundamental","pubTime":"2026-07-04 17:02","pubTimestamp":1783155759,"startTime":"0","endTime":"0","summary":"Analysts are intrested in these 5 stocks: ( ($ADBE) ), ( ($LRMR) ), ( ($PLTR) ), ( ($CVX) ) and ( ($AGNT) ). Here is a breakdown of their recent","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/weekend-updates/adobe-larimar-palantir-chevron-exp-trending-with-analysts?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/weekend-updates/adobe-larimar-palantir-chevron-exp-trending-with-analysts?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0278409577.USD","IGV","SGXZ99366536.SGD","IE00B5TLWC47.USD","BK4554","LU0061474960.USD","LU2129689431.USD","SHLD","LU0158827948.USD","SGXZ81514606.USD","IE00BQXX3F31.USD","LU1280957306.USD","LU2168564065.EUR","PTIR","LU2129689514.USD","IE0002270589.USD","LU1430594728.SGD","LU0557290698.USD","AIPI","LU1778281490.HKD","LU0345774631.USD","LU2129689605.HKD","BK4566","LU0234572021.USD","LU1633808545.USD","LU2458330243.SGD","IE00B2Q91V27.USD","BK4543","IXC","WEEI","BK4201","LU0289961442.SGD","LU1815333072.USD","LU0957791311.USD","LU0266512127.USD","PLYY","LU1084165304.USD","BK4588","LU0942090050.USD","LU0208291251.USD","LU0109391861.USD","LU0109392836.USD","BK4567","BK4581","LU0345774391.USD","VDE","LU2210149790.SGD","ADBE","LU2168564149.EUR","LU1162221912.USD","LU1712237335.SGD","LU0965509010.AUD","LU2317271919.USD","LU2236285917.USD","LU0057025933.USD","LU1235294995.USD","LU0889565833.HKD","IE00BFXG0V08.USD","PLT","LU2089284900.SGD","LU2360032135.SGD","LU0472753341.HKD","LU0265550359.USD","LU0070302665.USD","LU0320765489.SGD","SGXZ51526630.SGD","LU0708995401.HKD","LU1116320737.USD","LU1720051108.HKD","PLOO","LU2237438978.USD","GUNZ","IYE","PLTY","BK4585","LU2133065610.SGD","LU1823568750.SGD","LU0198837287.USD","LU2023251221.USD","SG9999002521.SGD","DRLL","LU1674673691.USD","LU0149725797.USD","LU0289739343.SGD","LU0345770308.USD","IE0009356076.USD","LU2458330169.SGD","SG9999000418.SGD","LU0889566641.SGD","LU0122376428.USD","LU0082616367.USD","LU0345770993.USD","IE00B19Z9Z06.USD","LU1066051498.USD","BK4550","IE00B894F039.SGD","PLTA","LU0965509101.SGD","LU1861559042.SGD","LU0320765059.SGD","LU0868494708.USD","LU0106261372.USD","PLTZ","LU1046421795.USD","ERX","LU2357305700.SGD","LU2381873111.SGD","LU1116320901.HKD","FENY","BK4533","LU0300736492.USD","LU1720051017.SGD","LU0368265418.SGD","LU1496350171.SGD","LU0234570918.USD","LU1585245621.USD","DIG","PLTD","LU0868494617.USD","BK4023","LRMR","IE00BQXX3D17.EUR","LU0314104364.USD","BK4570","LU0654597011.USD","LU0788109394.HKD","LU2168564495.EUR","BK4592","IE00BZ9MQY76.HKD","LU0965509283.SGD","LU1267930813.SGD","LU1366333091.USD","LU0170899867.USD","LU1119994496.HKD","BK4613","IE00BYQQ9H92.USD","LU1929549753.HKD","IE00B7SZLL34.SGD","BK4139","BK4547","PLTG","LU0456854461.SGD","LU1674673428.USD","LU1430597077.USD","LU0256863811.USD","LU1496350502.SGD","LU2125154778.USD","LU1691799644.USD","LU0861579265.USD","LU2210150020.SGD","BK4534","LU0006306889.USD","XLE","BK4527","BK4528","IE00B3CCJ963.GBP","LU0345780950.USD","LU0612318385.USD","LU2125154935.USD","IE000M9KFDE8.USD","PLTR","IE00BQXX3C00.GBP","IE00BGHQF524.EUR","IE00B19Z3B42.SGD","PLTU","LU2089283258.USD","LU1066053197.SGD","LU0348723411.USD","IE00B19Z9P08.USD","ADBG","LU1548497426.USD","LU0417517546.SGD","LU1267930730.SGD","LU0511384066.AUD","LU0719512351.SGD","LU0265550946.USD","PLTI","LU0069063385.USD","LU0345781412.USD","LU2168563687.JPY","IE00B19Z3581.USD","LU1623119135.USD","LU2168564222.USD","LU0320765646.SGD","LU0342679015.USD","LU0081259029.USD","LU1261432733.SGD","IE00B19Z9505.USD","PLTW","BK4559","LU1861558580.USD","LU1074936037.SGD","LU2095319765.USD","LU1803068979.SGD","LU0157215616.USD","LU0612318971.USD","SG9999001424.SGD","LU0630314457.HKD","LU0672654240.SGD","LU0640476718.USD","LU0300736062.USD","LU0792757196.USD","LU0098860793.USD","FTXN","CVX","IGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647537101","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2647537101","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647537101?lang=en_us&edition=fundamental","pubTime":"2026-06-30 18:40","pubTimestamp":1782816035,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Larimar Therapeutics (LRMR) and Arrowhead Pharmaceut...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-238?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-238?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LRMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647420534","title":"Larimar Therapeutics selloff a buying opportunity, says Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2647420534","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647420534?lang=en_us&edition=fundamental","pubTime":"2026-06-30 17:55","pubTimestamp":1782813321,"startTime":"0","endTime":"0","summary":"Citi recommends buying Larimar Therapeutics (LRMR) shares on yesterday’s weakness. FDA feedback indicates the company’s current data package is suf...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/larimar-therapeutics-selloff-a-buying-opportunity-says-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/larimar-therapeutics-selloff-a-buying-opportunity-says-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4588","LENZ","BK4139","LRMR","BK4539","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647930511","title":"Nomlabofusp Progress and Durable Efficacy Support Buy Rating on LRMR with Unchanged $25 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2647930511","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647930511?lang=en_us&edition=fundamental","pubTime":"2026-06-30 00:15","pubTimestamp":1782749742,"startTime":"0","endTime":"0","summary":"In a report released today, Francois Brisebois from LifeSci Capital maintained a Buy rating on Larimar Therapeutics, with a price target of $25.00....","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/nomlabofusp-progress-and-durable-efficacy-support-buy-rating-on-lrmr-with-unchanged-25-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/nomlabofusp-progress-and-durable-efficacy-support-buy-rating-on-lrmr-with-unchanged-25-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LRMR","PRGS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647036370","title":"Larimar stumbles on safety news even as BLA submission kicks off","url":"https://stock-news.laohu8.com/highlight/detail?id=2647036370","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647036370?lang=en_us&edition=fundamental","pubTime":"2026-06-29 22:25","pubTimestamp":1782743113,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics (LRMR) shares slid on Monday after the company reported new safety findings from its open label study of nomlabofusp for Fried...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/larimar-stumbles-on-safety-news-even-as-bla-submission-kicks-off-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/larimar-stumbles-on-safety-news-even-as-bla-submission-kicks-off-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LRMR"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.larimartx.com","stockEarnings":[{"period":"1week","weight":0.0628},{"period":"1month","weight":-0.1419},{"period":"3month","weight":-0.3805},{"period":"6month","weight":-0.365},{"period":"1year","weight":-0.3454},{"period":"ytd","weight":-0.3333}],"compareEarnings":[{"period":"1week","weight":-0.0199},{"period":"1month","weight":-0.0199},{"period":"3month","weight":-0.0201},{"period":"6month","weight":0.0311},{"period":"1year","weight":0.1039},{"period":"ytd","weight":0.1062}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.583333,"avgChangeRate":0.088036},{"month":2,"riseRate":0.583333,"avgChangeRate":0.090114},{"month":3,"riseRate":0.25,"avgChangeRate":-0.145723},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.03405},{"month":5,"riseRate":0.416667,"avgChangeRate":-0.096181},{"month":6,"riseRate":0.5,"avgChangeRate":-0.004489},{"month":7,"riseRate":0.538462,"avgChangeRate":-0.000858},{"month":8,"riseRate":0.461538,"avgChangeRate":0.075114},{"month":9,"riseRate":0.384615,"avgChangeRate":-0.011719},{"month":10,"riseRate":0.615385,"avgChangeRate":-0.044618},{"month":11,"riseRate":0.615385,"avgChangeRate":0.037653},{"month":12,"riseRate":0.583333,"avgChangeRate":0.050649}],"exchange":"NASDAQ","name":"Larimar Therapeutics, Inc.","nameEN":"Larimar Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.1","shortVersion":"4.52.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Larimar Therapeutics, Inc.(LRMR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Larimar Therapeutics, Inc.(LRMR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Larimar Therapeutics, Inc.,LRMR,Larimar Therapeutics, Inc.股票,Larimar Therapeutics, Inc.股票老虎,Larimar Therapeutics, Inc.股票老虎国际,Larimar Therapeutics, Inc.行情,Larimar Therapeutics, Inc.股票行情,Larimar Therapeutics, Inc.股价,Larimar Therapeutics, Inc.股市,Larimar Therapeutics, Inc.股票价格,Larimar Therapeutics, Inc.股票交易,Larimar Therapeutics, Inc.股票购买,Larimar Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Larimar Therapeutics, Inc.(LRMR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Larimar Therapeutics, Inc.(LRMR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}